How different is tirzepatide from the widely used GLP-1 RAs
Biofactors Morgan MJ, Kim Y-S (2022) Roles of RIPK3 in necroptosis, cell signaling, and disease
Who Benefits From Combination Therapy: Provider Decision Framework Combination therapy may be considered in patients with inadequate weight loss response to semaglutide monotherapy alone, documented treatment tolerance after initial side effects, and no contraindications to either agent
FDA-APPROVED INDICATIONS Type 2 diabetes As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus Limitations of use: has not been studied in patients with a history of pancreatitis TYPE 2 DIABETES RCT SURPASS-2 trial - Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes, NEJM (2021) [PubMed abstract] The SURPASS-2 trial enrolled 1879 adults with type 2 diabetes who were inadequately controlled with metformin at a dose of at least 1500 mg per day Main inclusion criteria Age 18 years T2DM uncontrolled with metformin at 1500 mg/day A1C of 7 - 10.5% BMI 25 and stable for 3 months Main exclusion criteria Type 1 diabetes GFR 50 ng/L
it is more expensive, but the protein content is 90% versus 70-80% in concentrate
Wear looser hairstyles: Avoid tight ponytails, braids, or buns that pull on your hair and stress the roots
